NYSE:ZYME

Zymeworks Stock News

Healthcare > Biotechnology

Buy ZYME

*Your capital is at risk

$22.86

-0.260 (-1.12%)

At Close: Jul 24, 2026

Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

08:30am, Thursday, 10'th Dec 2020

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three

Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

08:00am, Wednesday, 02'nd Dec 2020

ALAMEDA, Calif., SOUTH SAN FRANCISCO, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today anno

Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration With BeiGene

08:30am, Tuesday, 01'st Dec 2020

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGe

Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer

08:30am, Monday, 30'th Nov 2020

Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer

08:30am, Thursday, 19'th Nov 2020

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commi

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by